David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...
In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...
The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...
Tirzepatide is FDA-approved for weight loss as the brand-name drug Zepbound. It is also FDA-approved for type 2 diabetes management as the brand-name drug Mounjaro. Doctors can prescribe Mounjaro ...
Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
Mounjaro contains the active ingredient tirzepatide. (An active ingredient is what makes a drug work.) Another drug, Zepbound, also contains the same active ingredient and is approved for weight loss.
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
The FDA announced the end of the shortage of Novo Nordisk's drugs, Wegovy and Ozempic, which will impact sales of cheaper compounded versions. Compounded copies of Eli Lilly's drugs, Zepbound and ...